Eravacycline, the First Four Years: Health Outcomes and Tolerability Data for 19 Hospitals in 5 U.S. Regions From 2018 to 2022

Authors

A.J. Kunz Coyne
S. Alosaimy
K. Lucas
A.M. Lagnf
T. Morrisette
K.C. Molina
A. DeKerlegand
M. Rae Schrack
S.L. Kang-Birken
A.L.V. Hobbs
J. Agee
N.B. Perkins
M. Biagi
M. Pierce
J. Truong
Justin Andrade, Touro College of PharmacyFollow
J. Bouchard
T. Gore
M.A. King
B.M. Pullinger
K.C. Claeys
S. Herbin
R. Cosimi
S. Tart
M.P. Veve
B.M. Jones
L.M. Rojas
A.K. Feehan
M.R. Scipione
J.J. Zhao
P. Witucki
M.J. Rybak

Roles

Author

Document Type

Article

Publication Date

1-1-2023

Publication Title

Microbiology Spectrum

DOI

10.1128/spectrum.02351-23

Recommended Citation

Kunz Coyne, A., Alosaimy, S., Lucas, K., Lagnf, A., Morrisette, T., Molina, K., DeKerlegand, A., Rae Schrack, M., Kang-Birken, S., Hobbs, A., Agee, J., Perkins, N., Biagi, M., Pierce, M., Truong, J., Andrade, J., Bouchard, J., Gore, T., King, M., Pullinger, B., Claeys, K., Herbin, S., Cosimi, R., Tart, S., Veve, M., Jones, B., Rojas, L., Feehan, A., Scipione, M., Zhao, J., Witucki, P., & Rybak, M. (2023). Eravacycline, the First Four Years: Health Outcomes and Tolerability Data for 19 Hospitals in 5 U.S. Regions From 2018 to 2022. Microbiology Spectrum, 12 (1). https://doi.org/10.1128/spectrum.02351-23